Healthy volunteers. The aim is to test the effects of CRH on sleep electroencephalogram and sleep associated secretion of growth hormone and cortisol
Conditions
Interventions
Trade Name: CRH Ferring
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Corticorelin
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 100-
Sponsors
Max Planck Institute of Psychiatry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: healthy female volunteers, 20 to 30 years old; subjects must be capable to perform all examinations of the study; they must understand the aims of the study; written informed consent is required from each participant. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: participation in another study during the last month, psychiatric disorders, present or during life time, serious somatic disorders, pregnancy, nursing women, sleep disorders, substance abuse, intake of drugs during more than 2 days during the last 3 months, night work, transmeridian flight during the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To test the effect of CRH on the sleep electroencephalogram in healthy women;Secondary Objective: To test the effects of CRH on the sleep associated secretion of growth hormone and cortisol.;Primary end point(s): sleep electroencephalogram, sleep related secretion of cortisol and growth hormone | — |
Countries
Germany
Outcome results
None listed